Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China.
Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P. R. China.
Int J Biol Sci. 2021 May 13;17(8):2080-2088. doi: 10.7150/ijbs.60655. eCollection 2021.
Coronavirus disease 2019 (COVID-19), an infectious disease caused by Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has posed a persistent global threat. The transmission of SARS-CoV-2 is wide and swift. Rapid detection of the viral RNA and effective therapy are imperative to prevent the worldwide spread of the new infectious disease. Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR)- CRISPR-associated protein (Cas) system is an RNA-directed adaptive immune system, and it has been transformed into a gene editing tool. Applications of CRISPR-Cas system involves in many fields, such as human gene therapy, drug discovery and disease diagnosis. Under the background of COVID-19 pandemic, CRISPR-Cas system shows hidden capacity to fight the emergency in many aspects. This review will focus on the role of gene editing in COVID-19 diagnosis and treatment. We will describe the potential use of CRISPR-Cas-based system in combating COVID-19, from diagnosis to treatment. Furthermore, the limitation and perspectives of this novel technology are also evaluated.
新型冠状病毒肺炎（COVID-19），一种由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的传染病，持续对全球构成威胁。SARS-CoV-2 的传播范围广泛且迅速。快速检测病毒 RNA 和有效治疗对于防止新传染病的全球传播至关重要。规律成簇间隔短回文重复序列（CRISPR）- CRISPR 相关蛋白（Cas）系统是一种 RNA 导向的适应性免疫系统，现已转化为基因编辑工具。CRISPR-Cas 系统的应用涉及许多领域，如人类基因治疗、药物发现和疾病诊断。在 COVID-19 大流行的背景下，CRISPR-Cas 系统在许多方面显示出应对紧急情况的潜力。本文将重点介绍基因编辑在 COVID-19 诊断和治疗中的作用。我们将描述基于 CRISPR-Cas 的系统在 COVID-19 诊断和治疗方面的潜在用途，从诊断到治疗。此外，还评估了这项新技术的局限性和前景。
Zotero 插件